VLP Therapeutics Announces Phase 1 SBIR Grant Award from National Cancer Institute

10/11/17

VLP Therapeutics, LLC, a biotechnology company focusing on the research and development of therapeutic and preventative vaccines announced today the receipt of a Phase I grant from the National Cancer Institute under auspices of the Small Business Innovation Research (SBIR) program of the National Institutes of Health. The $298,729 grant under the Award Number R43CA217445 is focused on "the development of a novel Virus-Like Particle vaccine-based cancer immunotherapy targeting PD-L1" and will also explore broader immune checkpoint inhibition mechanisms.

The SBIR grant supports a VLP collaboration with Louis M Weiner, MD, Director of the Georgetown Lombardi Comprehensive Cancer Center at Georgetown University. The research will focus on determining immune response in mice and includes support for proof-of-concept studies at the Georgetown Lombardi. Weiner, an expert in cancer immunotherapeutics, is an unpaid member of the VLP Scientific Advisory Board.

Dr. Wataru Akahata, PhD, CEO of VLP Therapeutics said, "We are pleased to receive the SBIR grant from NCI, which supports the application of our VLP technology to the field of cancer immunotherapy. PD-L1 inhibition is a promising approach to treat several different cancers and it is our belief that a Virus-Like Particle vaccine-based approach to targeting checkpoint inhibition could become a valuable addition to the treatment paradigm."

About VLP Therapeutics

VLP Therapeutics was established in 2013 by seasoned biopharmaceutical veterans with the mission to develop innovative medical treatments which can transform traditional vaccines and targeted antibody therapies to address global unmet medical needs. Its vision is to combat 21st century global public health problems through its revolutionary next generation i-?VLP technology platform. VLP is currently developing vaccines to treat cancer and infectious diseases such as Malaria and Dengue Fever.

About i-? VLP Technology

The human immune system is biologically designed to protect us against disease. The immune system detects foreign objects such as viruses, bacteria or abnormal self-tissues (like cancer cells) in the body, and not only tries to eliminate these foreign objects, but also "memorizes" them so it can protect the body from them in the future. Vaccines utilize the immune system to protect us from various diseases.

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.

Baltimore Business Spotlight

Feature Your Business Here

Connect with these Baltimore Professionals on LinkedIn

  • Edwin Warfield

    Editor in Chief, Warfield Digital

    Connect
  • Jean Halle

    Independent Consultant

    Connect
  • Larry Lichtenauer

    President of Lawrence Howard & Associates

    Connect
  • Newt Fowler

    Partner at Womble Carlyle, LLP

    Connect
  • David Crowley

    Owner at Develop DC

    Connect
  • Carolyn Stinson

    Stinson Marketing Group

    Connect